$19.57−0.17 (−0.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Tyra Biosciences (TYRA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+42.3%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼38.7%
−119.9
FY21→FY25CAGR —
Free cash flow ($M)▼35.3%
−95.3
FY21→FY25CAGR —
Diluted EPS▼33.1%
−2.01
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+42.3%
41.9mn → 59.6mn diluted shares since FY22. Rising share count dilutes EPS. Growth must outrun it.
Capex
$141.0K
−78.8% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 143,997.0 | 102,928.0 | 80,077.0 | 62,518.0 | 43,008.0 | 20,636.0 | ▲28.5% | +49.4% |
Selling, general & admin | 38,405.0 | 29,834.0 | 24,100.0 | 17,427.0 | 15,919.0 | 5,652.0 | ▲23.8% | +51.6% |
Total operating expenses | 182,402.0 | 132,762.0 | 104,177.0 | 79,945.0 | 58,927.0 | 26,288.0 | ▲27.4% | +49.9% |
Operating incomefeeds ROC rank | −182,402.0 | −132,762.0 | −104,177.0 | −79,945.0 | −58,927.0 | −26,288.0 | ▼27.4% | — |
Other income, net | 12,583.0 | 12,815.0 | 17,696.0 | 10,811.0 | 3,602.0 | −6.0 | — | — |
Pretax income | −169,819.0 | −119,947.0 | −86,481.0 | −69,134.0 | −55,325.0 | −26,294.0 | ▼38.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −169,819.0 | −119,947.0 | −86,481.0 | −69,134.0 | −55,325.0 | −26,294.0 | ▼38.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.64 | −2.01 | −1.51 | −1.62 | −1.32 | −1.91 | ▼33.1% | — |
Diluted shares (mn) | 69.08 | 59.60 | 57.22 | 42.70 | 41.88 | 13.78 | ▲4.2% | +44.2% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-02 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

